Orveda

The unlikeliest part of this story is the resignation letter. In 2013, the woman who had spent two decades inside the world's largest cosmetics company walked away from running Lancome, a brand she had personally hauled out of a slump with launches like the perfume La Vie est belle and celebrity faces from Emma Watson to Lily Collins. Sue Y. Nabi had joined as a retail sales representative in 1993 and climbed to worldwide president of two flagship houses; few people leave that altitude voluntarily. She moved to London and disappeared into a question that the industry rarely asks: what would skincare look like if it cooperated with the skin's own biology rather than overriding it?

Her answer drew on an engineering degree and a personal turn toward naturopathy, Ayurveda and Taoist thinking, translated into a laboratory language of fermentation and biotechnology. The range she built rejects animal-derived ingredients entirely and is engineered to be gender-neutral, an unusual stance when most luxury skincare still sorts itself by demographic. The formulas lean on prebiotic complexes, marine enzymes and a kombucha-derived ferment, with the Omnipotent Concentrate positioned as the line's keystone. Textures are deliberately minimal-feeling, the opposite of the rich, perfumed creams Nabi spent years marketing elsewhere.

The twist that gives the venture its peculiar symmetry came in 2020, when Nabi was named chief executive of Coty, one of the very conglomerates she had competed against. Rather than fold her project away, the relationship evolved into a global distribution role for the brand, while creative ownership stayed with her partner. The result is a rare case of a beauty executive operating at the top of a mass-market giant while quietly stewarding a tiny, idiosyncratic luxury line built on contrarian principles, a side project assembled by someone who knew exactly how the machine she left behind actually works.

Sources:[1][2][3]